Introduction {#s1}
============

Tuberculosis (TB) continues to be a global health pandemic, killing more people than any other infection ([@bib69]). TB involves a complex host-pathogen interaction, with humans and *Mycobacterium tuberculosis* (Mtb) having undergone prolonged co-evolution ([@bib38]). TB has often been thought to primarily result from loss of immune control, because approximately 90% individuals infected with TB never progress to active disease, and this progression is increased in the context of immune deficiency; such as in cases of HIV infection, in infants, people with genetic deficiency of the IL-12/IFN-γ signalling pathway or after anti-TNF-α antibody treatment ([@bib41]). However, an emerging concept is that an excessive immune response to Mtb may be equally harmful. Standard disease paradigms predict that immune activation resulting from the administration of checkpoint inhibitors should lead to better control of Mtb infection ([@bib70]). However, counter-intuitively these agents seem to be activating TB, as evidenced by recent reports of TB developing in patients treated for malignancy with immune checkpoint inhibition, often rapidly after commencing therapy ([@bib25]; [@bib36]; [@bib9]; [@bib45]; [@bib30]; [@bib20]; [@bib28]; [@bib56]; [@bib3]; [@bib61]; [@bib65]). Consistent with this emerging clinical phenomenon, programmed death (PD-1) deficient mice are highly susceptible to TB, dying more rapidly than T-cell deficient mice ([@bib35]; [@bib2]).

PD-1 and its ligand PD-L1 are expressed in human granulomas ([@bib20]), suggesting a regulatory role at the site of disease. TB granulomas are hypoxic ([@bib5]), and PD-L1 is up-regulated by hypoxia ([@bib40]), further suggesting a mechanistic link between hypoxia and the PD-1/PD-L1 axis within TB lesions. In this study, we investigate the expression patterns of PD-1 and PDL-1 within TB infected human lung tissue and the relationship between PD-1 and anti-TB immunity. Next, using a human 3D cell culture model of TB ([@bib59]), we show that hypoxia increases expression of PD-1 and its ligands, that PD-1 inhibition increases Mtb growth. Surprisingly, TNF-α is primarily responsible for this effect, and TNF-α neutralisation reverses the anti-PD-1 induced phenotype.

Results {#s2}
=======

PD-1 is expressed in human TB granulomas but not in areas of immunopathology {#s2-1}
----------------------------------------------------------------------------

First, we investigated the presence and localisation of PD-1-expressing T cells in human pulmonary TB. We hypothesised that PD-1 would be expressed by T cells in the lung of patients with TB, and at a higher frequency than in the blood. In thirty-five patients undergoing medically indicated lung resection to treat TB or TB sequalae, PD-1 expression was measured on T cells isolated from the lung and matched blood samples, available for 23 patients, by flow cytometry. Overall, PD-1 expression in homogenized lung tissue was highly variable, with a trend towards increased PD-1 in both CD4 and CD8 T-cells from the lung compared to matched blood, which reached statistical significance for CD8 T-cells ([Figure 1A](#fig1){ref-type="fig"}). Lung tissue from healthy individuals was not available for study, however, the median frequency of 11% and 14% of PD-1+ CD4 and CD8 T-cells observed are generally lower than recently reported for healthy human lung tissue from organ donors of approximately 50% for both cell types ([@bib54]). As lung tissue is highly perfused with blood, distinguishing cells of lung or blood origin is challenging.

![PD-1 is expressed in human TB granulomas.\
(**A**) Analysis of PD-1 expression by T cells in the lung and peripheral circulation of thirty-five TB patients undergoing medically indicated lung resection. PD-1 shows a trend towards higher expression by lung CD4^+^ (**i**) and is significantly higher on lung CD8^+^ (ii) T cells. Significance analysed by one-tailed unpaired Mann-Whitney test. (**B**) Flow cytometric analysis of lung parenchyma CD4^+^ (i) and CD8^+^ (ii) T cells from TB patients based on the expression of PD-1, CD69 and CD103 demonstrates increased PD-1 expression in the resident T cells in the lung parenchymal cells. Significance analysed by Kruskal-Wallis test with Dunn's multiple comparison test. (**C**) Immunohistochemical staining for PD-1^+^, CD4^+^ and CD8^+^ expression in human lung TB granulomas. PD-1 is expressed around the central macrophage core in the same region as CD4^+^ (ii) and CD8^+^ (iii) T cells. Co-localization of PD-1 (blue), CD4^+^ (red) and CD8^+^ (yellow) using false colour of the immunostaining shows co-localisation of PD-1 with both CD4^+^ and CD8^+^ cells (purple and green respectively) (iv). Scale bar 100 μm. (**D**) PD-1 is not expressed in caseating granulomas where immunopathology is present in human lung biopsies (i). Six biopsies taken as part of routine clinical care were studied. CD4^+^ (ii) and CD8^+^ (iii) expressing cells are present in the same area, and so absence of PD-1 immunoreactivity is not due to lack of viable cells. Scale bar 200 μm.](elife-52668-fig1){#fig1}

To explore this further, we stained lung samples for canonical markers of tissue resident T-cells, CD69 and CD103 ([@bib54]). PD-1 expression on lung CD4 cells was predominantly restricted CD69+ T-cells, with a smaller proportion also expressing CD103 ([Figure 1B](#fig1){ref-type="fig"}, overall frequencies [Supplementary file 1](#supp1){ref-type="supplementary-material"}), consistent with a tissue resident phenotype and in contrast to PD-1 expressing cells in blood, which are largely CD69 negative ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Lung CD8 T-cells were also found to predominantly express CD69 in addition to CD103, again in contrast to CD8 T-cells in circulation. Therefore, these data are consistent with expression of PD-1 on lung tissue resident T-cells in patients with active or previous pulmonary TB infection. However, TB immunopathology is highly heterogenous within the lung and these analyses do not provide information as to the localization of PD-1 expression within TB lesions.

To address this question, we performed immunohistochemical analysis of human lung biopsies of patients with active TB. Within stable granulomas with an intact cellular structure, PD-1 expression was present around the central macrophage core ([Figure 1C--i](#fig1){ref-type="fig"}). Both CD4 and CD8 T cells were present in the granuloma ([Figure 1C--ii](#fig1){ref-type="fig"} and -iii), and co-localisation analysis demonstrated that a proportion of both T cell subtypes expressed PD-1 ([Figure 1C](#fig1){ref-type="fig"}-iv), consistent with the flow cytometry data. In contrast, in caseating granulomas with evident immunopathology, PD-1 expression was totally absent ([Figure 1D--i](#fig1){ref-type="fig"} and [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). The lack of immunoreactivity was not due to lack of viable cells, as CD4 and CD8 expressing T cells were present within the same area ([Figure 1D--ii](#fig1){ref-type="fig"} and -iii). Therefore, in human granulomas, PD-1 is expressed in areas where the host-pathogen interaction appears stable but is absent in regions of immunopathology.

The PD-1/PD-L1 axis is up-regulated in the 3D microsphere model {#s2-2}
---------------------------------------------------------------

Taken together, these data from Mtb infected patients demonstrate that PD-1 is expressed by lung resident T-cells and may be required to prevent destructive lung disease. However, whether this is a causal associated remains unclear. We therefore explored the biological role of PD-1 expression in a 3-dimensional (3D) human tissue culture model. TB is a human disease characterised by a prolonged host-pathogen interaction in 3D, and is regulated by the extracellular matrix, and previously we have previously developed a 3D cell culture model incorporating extracellular matrix to investigate TB pathogenesis ([@bib59]; [@bib60]). Here, we first studied migration of cells within the alginate-collagen matrix by performing time-lapse microscopy ([Figure 2A](#fig2){ref-type="fig"} and [Video 1](#video1){ref-type="video"}). For this experiment only, UV killed Mtb was used to permit the imaging outside the containment level three laboratory. From 24 hr, progressive accumulation occurs around a central infected core, resulting in a large multicellular granuloma by 48 hr with dynamic cellular movement similar to the T cell mobility observed in mouse BCG granulomas ([@bib16]).

![The PD-1/PD-L1 axis is upregulated in the 3D TB granuloma system.\
(**A**) Still images from time-lapse microscopy imaging demonstrating increasing cellular aggregation of PBMC around a focus of ultraviolet killed Mtb H37Rv in the 3D granuloma system at times 0, 12, 24 and 48 hr post encapsulation in the matrix. The Z projection shows the cells contained within the designated volume in a 2D reconstruction. Full time course in [Video 1](#video1){ref-type="video"}. (**B**) Gene expression of PD-1 and its ligands in the 3D microsphere model. RNA was extracted from live Mtb-infected PBMC and relative expression investigated by qRT-PCR at day four post infection. Open bars, normoxia, filled bars 1% hypoxia. PD-L1 and PD-L2 are upregulated by Mtb infection, and in 1% hypoxia PD-1 expression is increased and PD-L2 expression further augmented (n = 4). Results are normalised against the housekeeping genes GAPDH, β-Microbulin and FANTA and showed similar results. β-microglobulin used for (**B**). \*p\<0.05, \*\*p\<0.01. (**C--E**) Surface expression of PD-1 and PD-L1. PBMCs were decapsulated from Mtb-infected microspheres at day seven and surface expression of PD-1 and its ligand PD-L1 were analysed by flow cytometry. PD-1 is expressed in CD4^+^ (**C**) and CD8^+^(**D**) T cells in PBMC from Mtb infected microspheres incubated in normoxia. PD-1 expression was significantly upregulated in 1% hypoxia. Representative flow cytometry plots and level of expression of PD-1 by the CD4^+^ and CD8^+^ T cell fractions are shown (n = 4). (**E**) PD-L1 expression on CD14^+^CD11b^+^ cells within PBMC in Mtb infected microspheres is upregulated in both normoxia and 1% hypoxia at day 7 (n = 4). Significance of \*p\<0.05. (**F**) Growth of Mtb H37Rv ffLux+ in microspheres in normoxia and 1% hypoxia measured at day 3, 7 and 14. Hypoxia reduces Mtb growth. (**G**) Hypoxia inducible factor 1α (HIF-1α) mRNA levels were increased in Mtb-infected microspheres incubated in 1% hypoxia. RNA was extracted from decapsulated microspheres and normalised to uninfected microspheres in the same environment. Results were normalised to the housekeeping genes GAPDH, β-microglobulin and FANTA to check the housekeeping gene are not affected by hypoxia. Similar results all three of the housekeeping genes. β-microglobulin used for this graph. Significance \*\*\*p\<0.001.](elife-52668-fig2){#fig2}

###### Cell migration over 48 hr around a central cluster of macrophages infected with UV-killed Mtb within a 3D alginate-collagen matrix.

Migration is seen in the first 24 hr, without aggregation, and then progressive granuloma formation occurs.

We next investigated whether the PD-1/PD-L1 axis was up-regulated by infection in this 3D model, and found that Mtb infection increased PD-L1 and PD-L2 gene expression at 4 days post infection ([Figure 2B](#fig2){ref-type="fig"}). Furthermore, a hypoxic environment (1% oxygen) further increased PD-L2 expression. PD-1 gene expression was not increased at 72 hr by Mtb infection under normoxic conditions, but was up-regulated when infected cells were incubated in hypoxia ([Figure 2B](#fig2){ref-type="fig"}). The change in expression required both infection and hypoxia, as hypoxia did not increase PD-1 or PD-L1/2 expression alone ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). We then studied PD-1/PD-L1 cellular surface expression in microspheres by flow cytometry after one week of infection. Mtb infection slightly increased PD-1 surface expression on CD4^+^ T cells in normoxia, which was augmented by hypoxia ([Figure 2C](#fig2){ref-type="fig"}). Similarly, Mtb infection increased PD-1 expression on CD8^+^ T cells, which was greater in hypoxia ([Figure 2D](#fig2){ref-type="fig"}). Furthermore, on CD14^+^ CD11b^+^ cells, PD-L1 expression was increased by infection and more so in hypoxia ([Figure 2E](#fig2){ref-type="fig"}). To investigate whether the effect of hypoxia on increased PD-1/PD-L1 expression was due to altered Mtb growth, we studied proliferation using Mtb expressing firefly luciferase and also colony counting on Middlebrook 7H11 agar. Hypoxia inhibited Mtb growth by both readouts ([Figure 2F](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}). As expected, hypoxia also increased expression of the hypoxia inducible factor, HIF-1α, in host cells ([Figure 2G](#fig2){ref-type="fig"}), but did not have a significant effect on host cell survival ([Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"}). Therefore, the increased PD-1 and PD-L1/2 expression in hypoxia was not due to increased Mtb growth or a change in host cell viability.

PD-1 pathway inhibition increases Mtb growth in the 3D model {#s2-3}
------------------------------------------------------------

Having demonstrated that the PD-1/PD-L1 axis was up-regulated by infection in the 3D model, we investigated whether inhibition of this interaction modulated host control of Mtb. We initially studied chemical inhibitors of the PD-1/PD-L1 axis (Inhibitor 1, C~29~H~33~NO~5~) and found that blocking PD-1/PD-L1 binding increased Mtb growth in a dose-dependent manner ([Figure 3A](#fig3){ref-type="fig"}). This effect occurred in both normoxia and hypoxia ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). No effect of PD-1 inhibition on cell survival was noted at day 7 or day 14, utilising two different assays suited to each time point ([Figure 3B and C](#fig3){ref-type="fig"}). Next, we studied spartalizumab, a humanised monoclonal antibody with high-affinity to PD-1 that blocks the interaction with PD-L1 and PD-L2 ([@bib33]). Consistent with the chemical inhibition, PD-1 pathway inhibition using spartalizumab increased Mtb growth in normoxia in a dose-dependent manner ([Figure 3D](#fig3){ref-type="fig"}). Similarly, in hypoxia spartalizumab increased Mtb growth ([Figure 3E](#fig3){ref-type="fig"}). Microspheres must be restored to normoxia to measure Mtb luminescence, and therefore a single time point was analysed. Anti-PD-1 antibody treatment had no significant effect on cell survival in either normoxia or hypoxia ([Figure 3F](#fig3){ref-type="fig"}).

![PD-1 pathway inhibition increases Mtb growth.\
(**A**) Inhibition of PD-1 receptors by small chemical inhibitor one increases Mtb growth in a dose-response manner (1--1000 nM). Inhibitor concentration 1 nM (green), 10 nM (purple), 100 nM (blue) and 1 µM (red). (**B**) Inhibitor one was not toxic to Mtb-infected PBMC, analysed by CytoTox-Glo assay (Day 7). (**C**) Cellular toxicity was no different at day 14 as analysed by LDH release. Concentration 1 and 1000 nM were analysed for toxicity. (**D**) Spartalizumab, a therapeutic monoclonal anti-PD-1 antibody, progressively increased Mtb growth in microspheres in normoxia in a dose-dependent manner. (**E**) Spartalizumab also increased Mtb growth in hypoxia. Media (black), isotype (blue), spartalizumab 20 µg/ml (green) and 200 µg/ml (red). (**F**) The anti-PD-1 antibody had no effect on cell survival in microspheres in normoxia (clear bars) and 1% hypoxia (filled bars). Cytotoxity is determined by measuring LDH release at day 14 and normalized by the control. \*\*\*\*p\<0.0001.](elife-52668-fig3){#fig3}

PD-1 inhibition increases secretion of multiple cytokines and growth factors {#s2-4}
----------------------------------------------------------------------------

To investigate the underlying mechanism whereby PD-1 inhibition leads to increased Mtb growth, we studied secretion of cytokines, chemokines and growth factors by measuring accumulation in the media around Mtb-infected microspheres by Luminex array. Mtb infection increased secretion of numerous analytes ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), and inhibition of PD-1/PD-L1 signalling further significantly augmented secretion of twelve analytes compared to Mtb infection alone ([Figure 4](#fig4){ref-type="fig"}). A similar augmentation of analyte secretion was observed in hypoxic microspheres ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). The twelve analytes that were further increased above Mtb infection with concurrent PD-1 inhibition were IL-4, IL-6, IL-10, IL-12, TNF-α, IL-1RA, MIP-1α, MIP-1β, RANTES, G-CSF, GM-CSF and VEGF (individual concentrations, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Anti-PD-1 alone increased TNF-α secretion, although to a lesser effect than in combination with Mtb infection ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}).

![PD-1 inhibition increases secretion of multiple cytokines and growth factors.\
PD-1/PD-L1 signalling was inhibited by Spartalizumab, a humanized IgG4 anti-PD1 monoclonal antibody, in Mtb-infected microspheres at 20 and 200µ/ml in normoxia. Supernatants were collected at day 14 and accumulation of cytokines and growth factors was analysed by Luminex 35-multiplex assay. Concentrations were normalized to secretion by Mtb infected microspheres to demonstrate relative fold change, and individual concentrations are shown in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}. The experiment was performed twice with three replicates. Red font: \*\*p\<0.001 for Spartalizumab versus isotype control.](elife-52668-fig4){#fig4}

Exogenous TNF-α increases Mtb growth in microspheres {#s2-5}
----------------------------------------------------

To establish which of these factors might be associated with increased Mtb growth, we added the significantly upregulated analytes either individually or in combination pools to 3D microspheres in normoxia at 'low' ([Figure 5](#fig5){ref-type="fig"}) and 'high' concentrations ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}), as determined by the concentration measured in the secretion analysis. TNF-α was the dominant cytokine that increased Mtb growth, with other cytokines only having a minor effect ([Figure 5A](#fig5){ref-type="fig"}). Chemokines (RANTES, MIP-1α and MIP-1β) and growth factors (G-CSF) had no significant effect, while GM-CSF significantly increasing Mtb growth, but the effect was smaller than for TNF-α ([Figure 5B](#fig5){ref-type="fig"}). Additionally, the only cytokine combination that had a significant effect on Mtb growth was the pro-inflammatory pool containing TNF-α, IL-6 and IL-12 ([Figure 5C](#fig5){ref-type="fig"}). The addition of Th~2~ cytokines, chemokines or other growth factors had no significant effect (individual growth curves at 'high' concentration, [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Furthermore, TNF-α had a progressive dose-dependent effect increasing Mtb growth within microspheres ([Figure 5D](#fig5){ref-type="fig"}).

![Addition of TNF-α increases Mtb growth in microspheres in normoxia.\
Recombinant human G-CSF, GM-CSF, IL-4, IL-6, IL-10, IL-12, TNF-α, IL-1RA, MIP-1α, MIP-1β or RANTES were added either individually (**A** **and B**) or in combination pools (**C**) to Mtb-infected microspheres at 'low' concentrations, defined as that measured in media around spheres after anti-PD-1 treatment. Recombinant human TNF-α increases growth of Mtb, whilst other pro-inflammatory cytokines did not (**A**). GM-CSF has a lesser growth-promoting effect (**B**). The only combination pool that increased Mtb growth was the pro-inflammatory cytokine pool, containing TNF-α (**C**). (**D**) TNF-α results in a dose-dependent increase in the Mtb growth over time. (**E**) Anti-TNF-α neutralising antibodies partially suppress the increased Mtb growth caused by TNF-α augmentation. Anti-TNF-α from Thermo Fisher Scientific. (**F**) Anti-PD1 antibody incorporation within microspheres increases of Mtb growth at day 7, and this effect is reversed by concurrent anti-TNF-α neutralising antibodies within microspheres. The constituent of the cytokine pools are: Growth factor pool (GF: GM-CSF and G-CSF), Anti-Inflammatory cytokine pool (Anti-Inf: IL-10 and IL-1RA), Pro-Inflammatory cytokine pool (Pro-Inf: TNF-α, IL-6 and IL-12) and Chemokine pool (Chemo: RANTES, MIP-1α, MIP-1β).](elife-52668-fig5){#fig5}

To explore the effect of TNF-α further, we then generated microspheres incorporating infected PBMC with and without anti-TNF-α neutralising antibodies. Consistent with our initial observation, anti-TNF-α neutralising antibodies suppressed the TNF-mediated increased Mtb growth, with a partial reduction at each concentration studied of two different neutralising antibodies ([Figure 5E](#fig5){ref-type="fig"} and [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). Exogenous TNF-α modulated macrophage polarisation within microspheres, reducing CD80 expression at day 7 ([Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}). Therefore, we next investigated whether anti-PD-1-induced Mtb growth could be reversed by blocking TNF-α activity. Anti-PD-1 antibody treatment of infected cells again augmented Mtb growth, and this increased growth could be reversed by the incorporation of anti-TNF-α antibodies into the microspheres ([Figure 5F](#fig5){ref-type="fig"}). This confirms that an excess of TNF-α is the primary driver of increased Mtb growth caused by PD-1 inhibition in the 3D model.

TNF-α is highly expressed in TB granulomas and sputum TNF-α negatively correlates with circulating PD-1 expression {#s2-6}
------------------------------------------------------------------------------------------------------------------

Finally, to establish the in vivo relevance of our cell culture model findings, we performed immunohistochemical analysis of biopsies from patients with standard TB and anti-PD-1 associated TB. TNF-α was expressed within TB granulomas, with greater immunoreactivity than control lung tissue at the excision margin of lung cancer ([Figure 6A](#fig6){ref-type="fig"}). Consistent with our cell culture observations, TNF-α immunostaining was extensive in a biopsy from a patient that developed pulmonary TB whilst treated with pembrolizumab, an anti-PD-1 antibody ([Figure 6B](#fig6){ref-type="fig"}). Quantitative analysis of differences between standard TB and anti-PD-1 TB was not possible due to the unique nature of this clinical specimen, as TB diagnosis is usually made by bronchoalveolar lavage as opposed to percutaneous biopsy.

![TNF-α is expressed in human TB granulomas and sputum TNF-α concentrations negatively correlate with circulating PD-1 expression.\
(**A**) TNF-α is expressed within human lung TB granulomas, with greater immunoreactivity than control lung tissue at the excision margin of lung cancer (i and ii). Quantification of TNF-α immunostaining (n = 5) in TB cases was significantly higher than controls (n = 5) (iii). (**B**) TNF-α immunostaining was extensive in the lung granuloma of a patient that developed TB whilst treated with pembrolizumab, a humanized anti-PD-1 antibody (n = 1). (**C**) CD4^+^ T cell PD-1 expression on circulating PBMC negatively correlates with sputum TNF-α concentration in a separate cohort where paired sputum and PBMCs samples are available. Green dots, healthy controls; Black TB cases; Orange respiratory symptomatics. Analysis by Spearman's correlation analysis gave r-value of −0.341 with p=0.0484.](elife-52668-fig6){#fig6}

We then analysed the association between PD-1 expression by circulating CD4^+^ and CD8^+^ T cells and sputum TNF-α concentrations in a previously reported cohort ([@bib67]). Although this involved comparing PD-1 expression by circulating T cells, remote from the site of disease, with total TNF-α concentration in the sputum, we hypothesised that a reverse association would support the conclusion that PD-1 limits TNF-α secretion in patients. Consistent with this, CD4^+^ T cell PD-1 expression negatively correlated with sputum TNF-α, with a significant negative association despite the relatively low sample numbers, which would be expected to obscure an effect ([Figure 6C](#fig6){ref-type="fig"}).

Discussion {#s3}
==========

Although Mtb kills more people than any other infection worldwide, an enduring enigma is that 90% of those exposed exert lifelong control of the pathogen. In seminal post-mortem studies when TB was highly prevalent in the United States, Opie showed that 30% of humans who died from other causes had viable Mtb present in the lung apices ([@bib43]). Therefore, in the majority of exposed individuals, a stable relationship forms between host immune cells and Mtb without disease developing. Disseminated TB disease often develops in immunocompromised individuals, such as advanced HIV infection, newborn infants or following anti-TNF-α therapy, and this observation informs the view that TB can arise as a disease of a deficient immune response to the pathogen ([@bib41]).

However, the commonest form of human TB, and the one that leads to transmission, is apical pulmonary disease ([@bib18]). This occurs most frequently in young adults between the ages of 20--25 with the strongest recall response to Mtb antigens, as measured by the Mantoux test ([@bib11]). Therefore, these clinical observations demonstrate that infection results in a stable symbiosis between host and pathogen in the majority of individuals, and a pronounced immune response associates with the subsequent development of infectious pulmonary disease. The recently emerging clinical phenomenon of TB rapidly developing after initiating anti-PD-1 immunotherapy ([@bib25]; [@bib36]; [@bib9]; [@bib45]; [@bib30]; [@bib20]; [@bib28]; [@bib56]; [@bib3]; [@bib61]; [@bib65]) further reinforces that an excessive immune response in TB can be harmful.

PD-1 is expressed on T cells at the site of TB disease and PD-1 expression on circulating CD4+ T cells associates with bacterial load ([@bib13]). PD-1 expression is elevated in circulating CD4 T cells in TB ([@bib52]) and has been proposed to limit an effective host immune response. Consequently PD-1 inhibition has been advanced as a therapeutic target to accelerate clearance of infection ([@bib70]; [@bib52]; [@bib32]; [@bib53]; [@bib55]; [@bib31]). However, from an evolutionary perspective, PD-1 is proposed to limit immunopathology in the face of chronic antigenic stimulation ([@bib51]). Therefore, it is equally plausible, and indeed perhaps more logical, that PD-1/PD-L1 pathway up-regulation in TB is a physiologically appropriate response to the persistent pathogen. We found that hypoxia further up-regulated the PD-1/PD-L1/2 axis, consistent with hypoxia increasing expression in cancer ([@bib40]), and TB lesions are hypoxic both in model animals and human lesions ([@bib5]; [@bib66]). Analysis of the effect of hypoxia is complicated that both host and pathogen physiology are altered, with hypoxia causing reduced Mtb growth ([@bib14]; [@bib44]; [@bib24]) but also causing diverse host physiological changes. PD-1 may be particularly important in limiting excessive inflammation and pathology in conditions of low oxygen tension. TB reactivation following immune checkpoint blockade, and the extreme susceptibility of PD-1 deficient mice to Mtb infection ([@bib35]; [@bib2]), would support such a regulatory role, even though it runs counter to widely advanced disease paradigms.

Our work further highlights the double-edged sword of the host immune response in TB ([@bib17]). TNF-α is clearly essential to an effective host immune response to TB, as disease frequently develops after treatment with anti-TNF-α antibodies ([@bib34]), and TNF-α inhibits Mtb growth in zebrafish macrophages ([@bib10]) and human alveolar macrophages ([@bib29]). However, excessive TNF-α is also associated with poor outcomes in TB. In human cells, an excess of TNF-α can increase Mtb growth ([@bib6]; [@bib23]), consistent with our observations. In patients with active TB, TNF-α expression by Mtb-specific T cells is increased ([@bib27]; [@bib58]) and TNF-α associates with more severe radiological findings ([@bib8]; [@bib62]). In diverse model systems, excessive TNF-α has been shown to cause harmful inflammation ([@bib4]; [@bib57]; [@bib63]; [@bib48]; [@bib64]), consistent with TNF-α exerting a bell-shaped effect on host immunity, with either deficit or excess detrimental. Similarly, we report a deleterious effect of additional GM-CSF, in contrast to GM-CSF improving control of Mtb growth in murine macrophages ([@bib49]). This suggests that cytokine responses are highly dose and context dependent, potentially with each demonstrating non-linear responses leading to a complex matrix of what may denote the optimal cytokine profile for Mtb control. Consistent with our findings, in the one patient that developed TB on anti-PD-1 treatment where longitudinal samples are available, there was a spike in PPD-specific TNF-α expressing cells prior to with the development of active TB ([@bib3]), consistent with PD-1 acting as a regulator of TNF-α expression in TB. Taken together, these findings demonstrate a harmful effect of excessive TNF-α in TB.

We found that multiple cytokines and chemokines were increased after PD-1 inhibition, and therefore events in humans are likely to be more complex than TNF-α excess alone. The augmented inflammation may have multiple harmful effects, such as recruitment of excessive inflammatory cells and destruction of the extracellular matrix ([@bib7]; [@bib1]; [@bib39]), which favour Mtb growth. In the mouse model of TB, one key role of PD-1 is to limit IFN-γ production ([@bib50]), and we have shown that excess IFN-γ also accelerates Mtb growth in microspheres ([@bib59]). We did not show an effect of TNF-α on cell survival, although TNF-α has been reported to increase macrophage necrosis in the zebrafish model, via a mitochondrial-lysosomal-endoplasmic reticulum circuit ([@bib48]; [@bib47]). The effect of PD-1 inhibition on macrophage polarisation and survival warrants further investigation, as this is likely to be one determinant of outcome ([@bib37]; [@bib12]).

As in all in vitro systems, the bioelectrospray model has limitations ([@bib21]). For example, it does not permit the ingress of new inflammatory cells, and therefore can only be used to investigate the early events resulting from anti-PD-1 treatment, and not the recruitment of inflammatory cells by increased chemokine secretion. In addition, although it permits longer analysis of the host-pathogen interaction than other human primary cell culture systems, the 3 week standard experiment remains shorter than human infection, and so it models early events. We have not yet characterised which cells produce TNF-α, nor the wider phenotypic changes that result from inhibition of the PD-1 axis. The optimal approach would be to integrate single cell RNAseq to the analysis pipeline, so the phenotype of different cells can be comprehensively analysed. As microspheres can be readily dissolved by incubation in EDTA to release the cells, the system is suited for this technical development.

The common side effects of anti-PD-1 treatment in patients are termed immune related Adverse Events (irAEs), which are autoimmune in nature ([@bib46]). We have proposed that an autoimmune process may exacerbate pathology in TB ([@bib19]), and others have suggested that a loss of tolerance underlies progression to active TB ([@bib15]; [@bib42]). The common theme is that an excessive response to antigens, whether host or pathogen-derived, can drive disease in TB and our findings further support this conclusion. PD-1 may act to fine tune the balance between pro- and anti-inflammatory responses necessary to control infection without causing pathology. Notably, immune related adverse events to immune checkpoint inhibitors may be treated with anti-TNF-α antibodies ([@bib46]), suggesting TNF-α may be the primary driver of both autoimmunity and TB pathology after PD-1 treatment.

Our model provides the mechanistic insights into a clinical phenomenon with significant implications for future TB treatment and vaccine approaches. Simply driving a stronger immune response to Mtb seems unlikely to be beneficial, as clinical and epidemiological data suggest it may be harmful. For example, host-directed therapies may be designed to accelerate bacterial clearance whilst concurrently reducing immunopathological effects by appropriate skewing of macrophage phenotype. A more nuanced view considering the different immunological phases of TB is essential, differentiating events at the point of initial exposure from the late events at the apex of the lung, where excessive inflammation leads to immunopathology and transmission ([@bib22]). Defining the distinction between a protective and pathological immune response in human TB remains a key unanswered question, essential to inform new interventions to control the TB pandemic.

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                              Designation                                               Source or reference         Identifiers         Additional\
  (species) or resource                                                                                                                                                information
  ---------------------------------------------------------- --------------------------------------------------------- --------------------------- ------------------- ------------------------------------------------
  Strain, strain background (*Mycobacterium tuberculosis*)   H37Rv                                                     (From Ref: 20)                                  Used at multiple of infection of 0.1

  Strain, strain background (*Mycobacterium tuberculosis*)   H37Rv pMV306hsp+LuxAB+G13+CDE                             (From Ref: 20)                                  Used at multiple of infection of 0.1

  Strain, strain background (*Mycobacterium tuberculosis*)   H37Rv pMV306hsp encoding the wild-type FFluc              (From Ref: 20)                                  Used at multiple of infection of 0.1

  Biological sample (Antibodies)                                                                                                                                       

   Antibody                                                  anti-CD45-V500 Horizon (Clone no. HI30)                   BD Biosciences              Cat.No.563792       Monoclonal mouse antibody

   Antibody                                                  anti-CD3 Brilliant Violet 785 (Clone no. OKT3)            Biolegend                   Cat.No.317330       Monoclonal mouse antibody

   Antibody                                                  anti-CD3-PE (Clone no. HIT3a)                             Biolegend                   Cat.No.300308       Monoclonal mouse antibody

   Antibody                                                  anti-CD4 Brilliant Ultra Violet 496 (Clone no. SK3)       BD Bioscience               Cat.No.612937       Monoclonal mouse antibody

   Antibody                                                  anti-CD4-PerCP (Clone no. OKT4)                           Biolegend                   Cat.No.317432       Monoclonal mouse antibody

   Antibody                                                  anti-CD8 Brilliant Violet 605 (Clone no. RPA-T8)          Biolegend                   Cat.No.301040       Monoclonal mouse antibody

   Antibody                                                  anti-CD8-APC (Clone no. SK1)                              Biolegend                   Cat.No.344722       Monoclonal mouse antibody

   Antibody                                                  anti-CD103-APC (Clone no. Ber-ACT8)                       BD Biosciences              Cat.No.563883       Monoclonal mouse antibody

   Antibody                                                  anti-CD69 Brilliant Ultra Violet 395 (Clone no. FN50)     Biolegend                   Cat.No.310902       Monoclonal mouse antibody

   Antibody                                                  anti-HLA-DR-PerCP (Clone no. L243)                        Biolegend                   Cat.No.307628       Monoclonal mouse antibody

   Antibody                                                  anti-CD279-BB515 (Clone no. EH12.1)                       BD Biosciences              Cat.No.564494       Monoclonal mouse antibody

   Antibody                                                  anti- CD-274-BB515 (Clone no. MIH1)                       BD Biosciences              Cat.No.564554       Monoclonal mouse antibody

   Antibody                                                  anti-PD-1 Brilliant Violet 421 (Clone no.EH12.1)          BD Biosciences              Cat.No.562516       Monoclonal mouse antibody

   Antibody                                                  anti-CD11b-APC (Clone no. ICRF44)                         Biolegend                   Cat.No.301310       Monoclonal mouse antibody

   Antibody                                                  anti-CD45-APC/Cy7 (Clone no. 2D1)                         Biolegend                   Cat.No.368516       Monoclonal mouse antibody

   Antibody                                                  anti-CD14-AP/APC (Clone no. HCD14)                        Biolegend                   Cat.No.325608       Monoclonal mouse antibody

   Antibody                                                  anti-True-Stain Monocyte Blocker                          Biolegend                   Cat.No.426102       Monoclonal mouse antibody

   Antibody                                                  anti-CD4 (Clone no. M7310)                                DAKO                        Cat.No.M7310        Monoclonal mouse antibody

   Antibody                                                  anti-CD8 (Clone no. M7103)                                DAKO                        Cat.No. M7103       Monoclonal mouse antibody

   Antibody                                                  anti-PD1 (Clone no. ab5287)                               Abcam                       Cat.No.ab52587      Monoclonal mouse antibody

   Antibody                                                  anti-TNF-α (Clone no. ab1793)                             Abcam                       Cat.No.ab1793       Monoclonal mouse antibody

   Antibody                                                  Spartalizumab                                             Selleckchem                 Cat.No.A2017        20 µg/ml and 200 µg/ml, monoclonal, mouse IgG4

   Antibody                                                  IgG4                                                      Sino Biologicals            Cat.No.13505-HNAH   20 µg/ml and 200 µg/ml,monoclonal, mouse IgG4

   Antibody                                                  Mouse IgG1 kappa Isotype Control (P3.6.2.8.1),            Thermo Fisher Scientific    Cat.No.16-4714-82   50 µg/ml, mouse monoclonal IgG2A

   Antibody                                                  Mouse IgG1 Negative Control, clone Ci4                    Merck Life Sciences         Cat.No.MABC002      51 µg/ml, mouse monoclonal IgG2A

   Antibody                                                  anti-TNF-α                                                Thermo Fisher Scientific    Cat.No.16-7348-81   52 µg/ml, mouse monoclonal IgG2A

  Sequence-based reagent (Applied Biosystems TaqMan\         GAPDH                                                     Thermo Fisher Scientific    \#Hs02758991_g1     
  Gene Expression primers)                                                                                                                                             

                                                             β2-Microbulin                                             Thermo Fisher Scientific    \#Hs00608023_m1     

                                                             FNTA                                                      Thermo Fisher Scientific    \#Hs00357739_m1     

                                                             PDCD1                                                     Thermo Fisher Scientific    \#Hs01550088_m1     

                                                             CD274                                                     Thermo Fisher Scientific    \#Hs00204257_m1     

                                                             PDCD1LG2                                                  Thermo Fisher Scientific    \#Hs00228839_m1     

                                                             HIF-1α                                                    Thermo Fisher Scientific    \#Hs00153153_m1     

  Commercial assay or kit                                    CytoTox-Glo Cytotoxicity Assay                            Promega                     G9291               Commercial assay or kit

                                                             Lactate Dehydrogenase Activity Assay Kit                  Merck                       11 644 793 001      Commercial assay or kit

                                                             Cytokine and Chemokine 35-Plex Human ProcartaPlex Panel   Thermo Fisher Scientific    LHC6005M            Commercial assay or kit

  Chemical compound, drug                                    PD-1/PD-L1 Inhibitor 1                                    Cambridge Biosciences, UK   \#1675201-83-8      Chemical compound

                                                             Recombinant Human G-CSF                                   ImmunoTools                 Cat.No.11343115     1 ng/ml and 5 ng/ml

                                                             Recombinant Human GM-CSF                                  ImmunoTools                 Cat.No.11343125     0.25 ng/ml and 1.25 ng/ml

                                                             Recombinant Human IL-1RA/IL1 F3                           ImmunoTools                 Cat.No.11344876     1.25 ng/ml and 6.25 ng/ml

                                                             Recombinant Human IL-10                                   ImmunoTools                 Cat.No.11340105     0.2 ng/ml and 1 ng/ml

                                                             Recombinant Human IL-6                                    ImmunoTools                 Cat.No.11340066     10.0 ng/ml and 50.0 ng/ml

                                                             Recombinant Human IL-12                                   ImmunoTools                 Cat.No.11349125     0.5 ng/ml and 2.5 ng/ml

                                                             Recombinant Human TNF-α                                   ImmunoTools                 Cat.No.11343017     0.3 ng/ml, 1.5 ng/ml,7.5 ng/ml and 15 ng/ml

                                                             Recombinant Human IL-15                                   ImmunoTools                 Cat.No.11340155     0.5 ng/ml, 5 ng/ml and 50 ng/ml

                                                             Recombinant Human IL-17A                                  ImmunoTools                 Cat.No.11340176     1 ng/ml, 10 ng/ml and 100 ng/ml

                                                             Recombinant Human IL-17F                                  ImmunoTools                 Cat.No.11349176     1 ng/ml, 10 ng/ml and 100 ng/ml

                                                             Recombinant Human RANTES                                  ImmunoTools                 Cat.No.11343196     0.3 ng/ml and 1.5 ng/ml

                                                             Recombinant Human MIP-1α                                  ImmunoTools                 Cat.No.11343206     1.5 ng/ml and 7.5 ng/ml

                                                             Recombinant Human MIP-1β                                  ImmunoTools                 Cat.No.11343223     1.0 ng/ml and 5 ng/ml

                                                             Recombinant Human MCP                                     ImmunoTools                 Cat.No.11343386     1 ng/ml, 10 ng/ml and 100 ng/ml

  Software, algorithm                                        FlowJo                                                    BD Bioscences               version 10.6.1      Software

                                                             BD FACSDiva Software                                      BD Biosciences                                  Software

                                                             Graphpad Prism                                            GraphPad Software LLC       v7.05               Software
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*M. tuberculosis* culture {#s4-1}
-------------------------

*M. tuberculosis H37Rv* (Mtb) was cultured in Middlebrook 7H9 medium (supplemented with 10% ADC, 0.2% glycerol and 0.02% Tween 80) (BD Biosciences, Oxford). Bioluminescent Mtb containing luxABCDE (Mtb lux+) and Mtb expressing ffLuc (Mtb ffLuc+) were cultured with kanamycin 25 μg/ml. Luminescence was measured with either GloMax 20/20 single tube luminometer (Promega,UK) or GloMax Discover microplate reader (Promega,UK). Cultures at 1 × 10^8^ CFU/ml Mtb (OD = 0.6) were used for all experiments at multiplicity of infection (MOI) of 0.1. Live Mtb was used in all experiments apart from the time lapse microscopy, which used UV killed TB. Mtb colony counting was performed by serial dilution on Middlebrook 7H11 Agar. Bioluminescence from the Mtb ffLuc+ was induced using D-luciferin (ThermoFisher, UK) at a concentration of 750 μM in Hank's balanced salt solution (HBSS).

PBMC cell isolation from human blood {#s4-2}
------------------------------------

For the 3D microsphere experiments, PBMC were separated from single donor leukocyte cones (National Health Service Blood and Transfusion, Southampton, UK) by density gradient centrifugation over Ficoll-Paque (GE Healthcare Life Sciences). Ethical approval for these studies was provided by the National Research Ethics Service Committee South Central - Southampton A, ref 13/SC/0043.

Study participants for the correlation analysis of sputum-TNF-α with PD-1 expression on CD4^+^ and CD8^+^ T cells are the cross-sectional study individuals in a previously reported cohort ([@bib67]; [@bib68]). Participants were recruited from an outpatient clinic in Khayelitsha, South Africa and were either healthy volunteers, non-TB respiratory symptomatics or recently diagnosed TB patients. Flow cytometric analysis was performed on cryopreserved PBMC isolated from whole blood as previously reported ([@bib68]). The study was approved by the University of Cape Town Human Research Ethics Committee (REF 516/2011) and conducted in accordance with the Declaration of Helsinki.

Analysis of PD-1 expression in blood and lung of TB patients {#s4-3}
------------------------------------------------------------

Lung tissue and matched PBMC were obtained from the AHRI Lung study cohort approved by the Biomedical Research Ethics Committee (BREC) of the University of Kwa-Zulu Natal, BREC reference: BE019/13. All participants underwent surgical resection to treat TB related lung complications, including haemoptysis, bronchiectasis, persistent cavitatory disease, shrunken or collapsed lung or drug-resistant infection, at the King Dinuzulu Hospital in Durban, KwaZulu- Natal and Inkosi Albert Luthuli Central Hospital (IALCH) in Durban, KwaZulu-Natal. PBMC were isolated from whole blood using standard Ficoll-Histopaque (Sigma) density gradient centrifugation by standard protocol.

Lung tissues was cut into approximately 1 mm^3^ pieces, washed several times with cold HBSS (Lonza) and re-suspended in 8mls of pre-warmed digestion media R10 (RPMI supplemented with 10% FCS, 2 mM L-glutamate, 100 U/ml Penstrep), containing 0.5 mg/ml collagenase D (Roche) and 40 U/ml DNaseI (Roche), and transferred to GentleMACS C-tubes (Miltenyi) for mechanical digestion according to the manufacturer's instructions. The suspension was incubated for 30 min at 37°C, followed by an additional mechanical digestion step and another 30 min incubation step at 37°C. The final suspension was passed through a 70 μm cell strainer and washed twice in HBSS. PBMC and lung cells were phenotyped by surface staining with a near-infrared live/dead cell viability cell staining kit (Invitrogen) and a cocktail of fluorochrome conjugated antibodies: αCD45-V500 Horizon clone HI30 (BD Biosciences), αCD3 Brilliant Violet 785 clone OKT3 (Biolegend), αCD4 Brilliant Ultra Violet 496 clone SK3 (BD Bioscience), αCD8 Brilliant Violet 605 clone RPA-T8 (Biolegend), αCD103-APC clone Ber-ACT8 (BD Biosciences), αCD69 Brilliant Ultra Violet 395 clone FN50 (Brilliant Horizon), αPD-1 Brilliant Violet 421 clone EH12.1 (BD Biosciences). Cells were stained with 25 uL of antibody cocktail in the dark for 20 min at room temperature followed by washing with PBS, then fixed in 2% PFA. Data was acquired using BD Aria Fusion cytometer and analyzed using FlowJo Software v.9.9 (Treestar Inc, Ashland, OR).

Immunohistochemistry of paraffin-fixed tissue {#s4-4}
---------------------------------------------

Immunohistochemical analysis was performed on paraffin-embedded lung tissue from patients with pulmonary TB and lung cancer that were mounted at 4 µm thin onto APS coated glass slides and dried, using the following antibodies: anti-CD4 (Clone no. M7310) (DAKO), anti-CD8 (Clone no. M7103) (DAKO), anti-PD1 (Clone no. ab5287) (Abcam) and anti-TNF-α (Clone no. ab1793) (Abcam). Staining was done at optimised concentrations usingrecommended buffers for each antibody.

Microencapsulation of cells {#s4-5}
---------------------------

Microspheres were generated with an electrostatic generator (Nisco, Zurich, Switzerland) as described previously ([@bib60]). Briefly, PBMC were infected overnight with Mtb in a 250 cm^2^ flask, cells were detached, pelleted and mixed with 1.5% sterile alginate (Pronova UP MVG alginate, Nova Matrix, Norway) and 1 mg/mL collagen (Advanced BioMatrix, USA) at a final concentration of 5 × 10^6^ cells/ml. The cell-alginate suspension was injected into the bead generator where microspheres were formed in an ionotropic gelling bath of 100 mM CaCl~2~ in HBSS. After washing twice with HBSS with Ca^2+^/Mg^2+^, microspheres were transferred in RPMI 1640 medium containing 10% human AB serum and incubated at 37°C. Microspheres were either dispensed into eppendorfs, which were then randomly allocated to different environmental conditions, or plated into a 96-well plate with conditions in triplicate according to a pre-determined template. For experiments in hypoxia, microspheres were incubated in 1% oxygen in Galaxy 48 R CO~2~ incubator (Eppendorf, UK) until analysis. Supernatants were collected at defined time points. Time points described are days post infection.

Live cell imaging {#s4-6}
-----------------

Uninfected or UV killed Mtb infected cells suspended in alginate-collagen matrix were plated in an eight well μ-Slide (ibidi GmbH, Germany). HBSS containing Ca^2+^ was used for cross-linking of alginate in the extracellular matrix for 15 min and then replaced with RPMI medium with 10% human AB serum. Samples were imaged using an Olympus IX81 time-lapse microscope with temperature of 37°C and CO~2~ concentration 5%. Z-stacks 200 µm in height were captured at one position in each sample every 30 min for 48 hr. Images were exported as tif files and opened in ImageJ.

PD-1/PD-L1 Inhibition {#s4-7}
---------------------

Small chemical inhibition of PD-1/PD-L1 signalling was by PD-1/PD-L1 Inhibitor 1 (CAS Registry \#1675201-83-8, Cambridge Biosciences, UK), a compound that competitively blocks the interaction of PD-1 with it ligand protein PD-L1 ([@bib26]). Inhibitor one was prepared in DMSO (Sigma-Aldrich,UK) at a concentration of 6.3 mM and dissolved to a concentration of 1 nM, 10 nM, 100 nM and 1 μM in complete media and added to media around microspheres on the day after encapsulation. Luminescence was monitored on specific days. For the microspheres incubated in hypoxic conditions, measurement of luminescence was repeated for every 30 min after the addition of luciferin until the reading plateaued, which was usually 2 hr.

In antibody inhibitory experiments, spartalizumab (Selleckchem, Germany), a humanised IgG4 anti-PD1 monoclonal antibody, was used to inhibit of PD-1/PD-L1 signalling in microspheres. Briefly, cells were infected with Mtb overnight, pelleted and then a suspension of anti-PD1 antibodies (20 and 200 μg/ml) were added and pre-incubated for 1 hr. Cells were then encapsulated within microspheres and kept for 14 days in either normoxia or 1% oxygen at 37°C and 5% CO~2~. Mtb growth was measured using luminescence and supernatants were taken for either cytokine or LDH measurement. An IgG4 human antibody was used at the same concentration as a control.

Cell toxicity assays {#s4-8}
--------------------

Lactate dehydrogenase (LDH) release in the supernatants collected at different time points was analysed by a colorimetric activity assay as per manufacturer's instructions (Roche, Burgess Hill, United Kingdom). As a second assay, CytoTox-Glo Cytotoxicity Assay (Promega) was used, which measures dead-cell protease activity released from cells without membrane integrity using a luminogenic peptide substrate, the AAF-Glo Substrate. Luminescence from 96-well plates was analysed by GloMax Discover (Promega). The LDH assay was suited for later time points, as this could be performed on microspheres in eppendorfs, while the CytoTox glow required analysis in 96 well plates and so was best suited to analysis in the first week.

Gene expression analysis {#s4-9}
------------------------

All the reagents were sourced from ThermoFisher Scientific (Paisley, UK). In brief, microspheres were decapsulated with 5 mM EDTA, cells were pelleted and immediately lysed using TRIzol Reagent. RNA was transcribed using High Capacity cDNA Reverse Transcription kit. TaqMan Universal master mix and primers specific for genes were GAPDH (\#Hs02758991_g1), β2-Microbulin (\#Hs00608023_m1), FNTA (\#Hs00357739_m1), PDCD1 (\#Hs01550088_m1), CD274 (\#Hs00204257_m1), PDCD1LG2 (\#Hs00228839_m1) and HIF-1α (Hs00153153_m1) were used for qPCR according to the manufacturer's instructions and the comparative threshold (CT) method was employed to analyse all qPCR data.

Immunophenotyping of cells from microspheres {#s4-10}
--------------------------------------------

Microspheres were decapsulated with 5 mM EDTA in HBSS with no Ca^2+^/Mg^2+^ at day seven after encapsulation and 2 million cells prepared for staining in RPMI with 5% foetal bovine serum. To measure the expression of PD-1 in CD4^+^ and CD8^+^ T cells and PD-L1 expression in CD14^+^CD11b^+^ cells, the following antibody panel was used: CD3-PE (clone HIT3a, Biolegend), HLA-DR-PerCP (clone L243, Biolegend), CD4-PerCP (clone OKT4, Biolegend), CD8-APC (clone SK1, Biolegend), CD11b-APC (clone ICRF44, Biolegend), CD45-APC/Cy7 (clone 2D1, Biolegend), CD14-AP/APC (clone HCD14, Biolegend), CD279-BB515 (Clone EH12.1, BD), CD-274-BB515 (Clone MIH1, BD) and True-Stain Monocyte Blocker (Biolegend, USA). Gates were defined using fluorescence minus one control after exclusion of the dead cells using Live/Dead fixable stain (ThermoFisher, UK). Gating strategy is provided in [Figure 5---figure supplement 4](#fig5s4){ref-type="fig"}. Cells were acquired after fixing them in 2% paraformaldehyde in HBSS for 1 hr using FACSAria (Becton Dickinson, UK) and analysed by FACSDiva software (Becton Dickinson) and Flow Jo version 10 (Treestar).

Cytokine supplementation {#s4-11}
------------------------

Microspheres were incubated in RPMI 1640 with 10% AB serum in an opaque 12-well tissue culture plate with G-CSF, GM-CSF, IL-1RA, IL-6, IL-10, IL-12, IL-15, IL-17A, IL-17F, TNF-α, RANTES, MIP-1α, MIP-1β and MCP at two concentrations determined by the cellular experiments, at 37°C and 5% CO~2~. All the cytokines were purchased from ImmunoTools (Germany), suspended in RPMI with 0.1% human serum and kept at −80°C until use. Bacterial growth was monitored with luminescence using GloMax Discover microplate reader (Promega,UK).

Luminex analysis {#s4-12}
----------------

Samples were sterilised by filtration through a 0.22 μM Durapore membrane (MerkMillipore). Concentrations of cytokines (ThermoFisher, UK) were determined using a Bioplex 200 platform (Bio-Rad, UK) according to the manufacturer's protocol and quantified per milligram of total protein measured by Bradford assay (Biorad).

Statistical analysis {#s4-13}
--------------------

All experiments were performed on a minimum of 2 occasions from separate donors as biological replicates and on each occasion with a minimum of 3 technical replicates. Some donor-to-donor variation occurred in terms of absolute RLU, as expected in the analysis of primary human cells, but the direction of effects were always consistent. Data presented are from a representative donor and include the mean and SEM. Analysis was performed in Graphpad Prism v7.05. Students t-test was used to compare pairs and ANOVA with Tukey's correction for multiple comparisons for groups of 3 or more groups where it was appropriate. For the flow cytometric analysis of clinical samples, data were analysed using Mann-Whitney test for comparing pairs and Kruskal-Wallis test with Dunn's multiple comparisons test for three or more group.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

This work uses an innovative microsphere 3-D model to dissect host-pathogen interactions during human infection with *Mycobacterium tuberculosis* by investigating the impact of PD-1 inhibition on infection outcome. With the microsphere model, the authors show that inhibition of PD-1 is detrimental to host control of Mtb due to excessive TNF production, thereby contributing to tuberculosis susceptibility from PD1 blockers.

**Decision letter after peer review:**

Thank you for submitting your article \"Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Tadatsugu Taniguchi as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Alissa Rothchild (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Tezera et al. extend previous findings using a 3D biospray cell culture model to dissect host-pathogen interactions during human Mtb infection by investigating the impact of PD-1 blockade on infection. The authors demonstrate that PD-1 is expressed on lung resident T cells from TB patients and that PD-1 and PD-L1 expression increases following infection of PBMCs in the 3D model. They show that inhibition of PD-1 is detrimental to host control of Mtb due to excessive TNF production. This is an interesting paper, but as the authors themselves point out, it is already known that PD-1 blockade leads to an increase in cytokine production and loss of Mtb control. The dogma thus far, is that excessive Th1 responses are the mechanism of TB susceptibility in PD-1 blockers cases. This paper fights this dogma; and says that the pro-inflammatory cytokines drive Mtb replication, and this excessive cytokine response is what is at the root of TB susceptibility from PD1 blockers. The authors have designed a number of experiments with their innovative three-dimensional model, called the microsphere.

The reviewers were enthusiastic about the novel application of microsphere to this contemporary issue, but given that other studies have demonstrated a clear roles for TNF during Mtb infection, they raised concerns about lack of mechanistic detail as to how PD-1 inhibition increases TNF production in this 3D model and what impact excessive TNF is having on immune cell interactions in the microsphere system. In addition, some results (see below) need further data and statistics to support the conclusions.

Essential revisions:

1\) Figure 1: PD-1 is expressed in granulomas but not in areas of immunopathology. This is an important point being made, with human samples, but the first statistical testing is PD1 levels in tissue cells versus blood cells. Perhaps a) cells become PD1 positive in tissue, b) PD1 cells hone to the tissue, c) other? Though p-values are reported, it wasn\'t clear what the hypothesis was. It was much clearer in the tissue sections when the authors set out to determine whether the PD1+ were and were not, in the tissue. Maybe the statistical testing should be reserved for the data that directly address the experimental hypotheses? In Figure 1A, there are \~ 35 dots in the lung plot with a median frequency of PD1+ cells of about 15%. Does this mean that the authors studied 35 independent samples from 35 patients? Please describe the N for the pathology samples in the Results (perhaps this was in a supplementary file?). It seems that the biologic difference between blood and lung is very thin and the statistical difference is driven by the large number of dots. It would be important to clarify the number of independent lung samples studied for this figure. Finally, in the text, the authors conclude by saying: \"PD-1 is expressed by lung resident T-cells and may be required to prevent destructive lung disease.\" I believe this is based on an inverse correlation. It might be preferable to conclude the section with what is observed, then introduce the hypothesis in the next section. There are other critical questions that must be addressed in Figure 1. How does the frequency of PD-1 expressing T cells in TB patients compare to healthy controls? It would be helpful in Figure 1A to compare the frequencies (at least in the blood) to those in healthy controls to understand whether the increase in PD-1 is lung specific or systemic during Mtb infection. Second, in Figure 1B, PD-1 expression appears to be highest on the CD103+ CD69+ population for CD8^+^ T cells, but CD103 does not seem to mark the CD4^+^ T population with the highest PD-1 expression. Is CD103 known to mark tissue residency for CD4^+^ T cells like it does for CD8^+^ T cells? If not, it might be better to leave this marker out of the analysis in Figure 1B-I for clarity. It would also be useful to include the overall frequencies of each of the four CD103/CD69 populations for both CD4^+^ and CD8^+^ T cells from lung parenchyma to better understand which of the four populations are common or rare in the human lung.

2\) The effect of different cytokines and chemokines on Mtb growth within the microspheres in Figure 5A-C and Figure 5---figure supplement 1 and their description in the text is confusing. Can the authors clarify what \"Chemokines (RANTES, MIP-1a and MIP-1b) and growth factors (G-CSF and GM-CSF) had a small growth-promoting effect\" means given that only GM-CSF led to significant increases in Mtb growth in Figure 5B? Additionally, some of the supplementary data in Figure 5---figure supplement 1 does not match up with the results shown in Figure 5. For example, Figure 5B shows no difference in Mtb growth with the addition of IL-1RA, but there is a significant increase in Mtb growth following IL-1RA treatment shown in Figure 5---figure supplement 1. Close reading of the figure legends shows that the concentration of cytokines/chemokines added in Figure 5---figure supplement 1 was 5 times higher, but there is no mention of this in the text or explanation of why. Please clarify why these two different experiments were performed and provide an interpretation of the differing results. Microsphere have disparate cells which are constituents of peripheral blood mononuclear cells. This might include T cells, myeloid cells, and matrix. Please discuss how these data compare to previous experiments performed on isolated Mtb infected cells. Specifically, other groups Hirsch et al., 1994 showed that TNF in Mtb infected macrophages interfered with Mtb replication. Other have shown how early macrophage events are interfered with my TBF blockers, that would allow Mtb replication. These data will be compared with Figure 5A. Why is the data so different? Sam Behar\'s lab has demonstrated that T-cell derived GMCSF diminishes Mtb replication (MBio 2017 Oct). This will be contrasted with data, Figure 5B. Please discuss the discrepancy.

3\) The authors very nicely demonstrate that the increase in Mtb growth is dependent on TNF production and cite several papers that link TNF to Mtb growth by different mechanisms including \"recruitment of excessive inflammatory cells and destruction of the extracellular matrix\" and \"cell survival.\" Is it possible to identify which mechanism is responsible for the Mtb growth phenotype in this 3D culture model or at least rule out any of these possibilities? For example, following PD-1 blockade with or without anti-TNF antibodies is there a change in the viability of myeloid cells or a difference in the proportions of cell populations within the microspheres? How do the authors envision the mechanism in this system might be similar or different from other PD-1 inhibition studies? For instance, there is obviously no inflammatory cell recruitment occurring within the microspheres but perhaps TNF production leads to changes in population frequencies that impact bacterial control. The study would be strengthened by an analysis to determine which cell type or mechanism is responsible for the excess TNF production following PD-1 blockade (CD4^+^ T cells, CD8^+^ T cells, or an innate cell type). At minimum, the authors should include a nuanced which of the mechanisms would be relevant to their model and why.

10.7554/eLife.52668.sa2

Author response

> Essential revisions:
>
> 1\) Figure 1: PD-1 is expressed in granulomas but not in areas of immunopathology. This is an important point being made, with human samples, but the first statistical testing is PD1 levels in tissue cells versus blood cells. Perhaps a) cells become PD1 positive in tissue, b) PD1 cells hone to the tissue, c) other? Though p-values are reported, it wasn\'t clear what the hypothesis was. It was much clearer in the tissue sections when the authors set out to determine whether the PD1+ were and were not, in the tissue. Maybe the statistical testing should be reserved for the data that directly address the experimental hypotheses?

We accept this comment. The point that we were trying to make was that PD-1 is expressed by T cells within the lung of patients with TB, and so we first show that PD-1 expressed in the lung, and this is at a higher level than in the blood. We have amended the statistical analysis in panel B as suggested to address the experimental hypothesis and to make the conclusions we are drawing clearer. We have also edited the text describing these analyses to make the hypothesis being tested apparent.

> In Figure 1A, there are \~ 35 dots in the lung plot with a median frequency of PD1+ cells of about 15%. Does this mean that the authors studied 35 independent samples from 35 patients?

We have clarified the number in the text and legend to show that each dot represents a different patient, and there were 35 patients studied.

> Please describe the N for the pathology samples in the Results (perhaps this was in a supplementary file?).

We have stated the N in the legend, which was 6 TB clinical biopsies.

> It seems that the biologic difference between blood and lung is very thin and the statistical difference is driven by the large number of dots. It would be important to clarify the number of independent lung samples studied for this figure.

We have clarified the number in the legend, which was 35 samples.

> Finally, in the text, the authors conclude by saying: \"PD-1 is expressed by lung resident T-cells and may be required to prevent destructive lung disease.\" I believe this is based on an inverse correlation. It might be preferable to conclude the section with what is observed, then introduce the hypothesis in the next section.

We agree with this point and have amended the text as suggested, moving the hypothesis to the next section.

> There are other critical questions that must be addressed in Figure 1. How does the frequency of PD-1 expressing T cells in TB patients compare to healthy controls? It would be helpful in Figure 1A to compare the frequencies (at least in the blood) to those in healthy controls to understand whether the increase in PD-1 is lung specific or systemic during Mtb infection.

PD-1 and PD-L1/2 expression has previously been reported to be elevated in circulating PBMCs in TB, in work we cited (Shen et al., 2016), and we now expand on this in the second paragraph of the Discussion. For the lung, the reviewer raises an important question. Unfortunately, out studies use lung tissue removed by surgical resection of patients with complications of TB, such as massive haemoptysis, and thus healthy control material is not easily obtainable to make these comparisons. Recently published work looking at healthy lungs from organ donors does report high PD-1 expression. This is now referenced and discussed in the first paragraph of the subsection "PD-1 is expressed in human TB granulomas but not in areas of immunopathology".

> Second, in Figure 1B, PD-1 expression appears to be highest on the CD103+ CD69+ population for CD8^+^ T cells, but CD103 does not seem to mark the CD4^+^ T population with the highest PD-1 expression. Is CD103 known to mark tissue residency for CD4^+^ T cells like it does for CD8^+^ T cells? If not, it might be better to leave this marker out of the analysis in Figure 1B-I for clarity.

Human lung tissue does contain CD69+CD103+ CD4 and CD8 T-cells. Although CD103+ expression in higher in the CD8^+^ fraction, approximately 20% of CD69+ve T-cells in healthy lung express CD103+, as published (Snyder et al., 2019). We clarify this point and cite this in the second paragraph of the subsection "PD-1 is expressed in human TB granulomas but not in areas of immunopathology".

> It would also be useful to include the overall frequencies of each of the four CD103/CD69 populations for both CD4^+^ and CD8^+^ T cells from lung parenchyma to better understand which of the four populations are common or rare in the human lung.

We now include these data as Supplementary file 1.

> 2\) The effect of different cytokines and chemokines on Mtb growth within the microspheres in Figure 5A-C and Figure 5---figure supplement 1 and their description in the text is confusing. Can the authors clarify what \"Chemokines (RANTES, MIP-1a and MIP-1b) and growth factors (G-CSF and GM-CSF) had a small growth-promoting effect\" means given that only GM-CSF led to significant increases in Mtb growth in Figure 5B?

We apologise for the lack of clarity. The experiments were performed twice, with two concentrations of cytokines on each occasion. One concentration was that measured in the cell culture supernatants (Figure 4), and the second was 5x this, to allow for potential concentration gradients from the exterior to the centre of the microspheres. The 1x concentration ("low") experiments are presented in the main manuscript, whilst the 5x concentration ("high") experiments are in the supplementary material. The direction of effect of each cytokine was the same for low and high concentrations, though with a greater effect size for the 5x. We have provided clarification in --the first paragraph of the subsection "Exogenous TNF-α increases Mtb growth in microspheres" and Figure 5 and Figure 5---figure supplement 1 legend to avoid the confusion. We have also edited to state that only GM-CSF had a significant increase in addition to TNF-α, as the reviewer correctly states that we over-reported the minor chemokine effect.

> Additionally, some the supplementary data in Figure 5---figure supplement 1 does not match up with the results shown in Figure 5. For example, Figure 5B shows no difference in Mtb growth with the addition of IL-1RA, but there is a significant increase in Mtb growth following IL-1RA treatment shown in Figure 5---figure supplement 1. Close reading of the figure legends shows that the concentration of cytokines/chemokines added in Figure 5---figure supplement 1 was 5 times higher, but there is no mention of this in the text or explanation of why. Please clarify why these two different experiments were performed and provide an interpretation of the differing results.

We addressed this critique above, and apologise that the manuscript was not sufficiently clear about the concentration differences between Figure 5 and Figure 5---figure supplement 1, and the rationale for using these two concentrations. We have further clarified in the first paragraph of the subsection "Exogenous TNF-α increases Mtb growth in microspheres" and in the respective figure legends.

> Microsphere have disparate cells which are constituents of peripheral blood mononuclear cells. This might include T cells, myeloid cells, and matrix. Please discuss how these data compare to previous experiments performed on isolated Mtb infected cells. Specifically, other groups Hirsch et al., 1994 showed that TNF in Mtb infected macrophages interfered with Mtb replication. Other have shown how early macrophage events are interfered with my TBF blockers, that would allow Mtb replication. These data will be compared with Figure 5A. Why is the data so different? Sam Behar\'s lab has demonstrated that T-cell derived GMCSF diminishes Mtb replication (MBio 2017 Oct). This will be contrasted with data, Figure 5B. Please discuss the discrepancy.

We agree that the effect of individual cytokines is likely to be both concentration, context and host dependent, and that our results are at odds with those that show a protective effect of GM-CSF from the Behar laboratory that were performed in murine macrophages. We propose that for several cytokines there is a bell-shaped response curve, with an optimal concentration for mycobacterial control, and either very low or high concentrations being deleterious, as is emerging for TNF-α, from both our work and other groups. We accept that these concepts were not sufficiently commented on in the original submission, and have extended the Discussion (fourth paragraph), putting our results in the context of the previous work cited above, and we have expanded on the balance between protective and harmful concentrations of cytokines.

> 3\) The authors very nicely demonstrate that the increase in Mtb growth is dependent on TNF production and cite several papers that link TNF to Mtb growth by different mechanisms including \"recruitment of excessive inflammatory cells and destruction of the extracellular matrix\" and \"cell survival.\" Is it possible to identify which mechanism is responsible for the Mtb growth phenotype in this 3D culture model or at least rule out any of these possibilities? For example, following PD-1 blockade with or without anti-TNF antibodies is there a change in the viability of myeloid cells or a difference in the proportions of cell populations within the microspheres?

To address this comment, we have performed additional experiments studying macrophage polarisation with addition of TNF-α (Figure 5---figure supplement 3). High TNF concentrations lead to a reduction in CD80 expression, which associate with macrophages more permissive to Mtb growth. We now discuss this in the last paragraph of the subsection "Exogenous TNF-α increases Mtb growth in microspheres". Further mechanistic dissection of the phenomenon will be possible within the model, which we propose to do by single cell sequencing of cells released from microspheres as discussed in the sixth paragraph of the Discussion. However, this work is beyond the scope of the current manuscript and clearly cannot be performed within the time frame available.

> How do the authors envision the mechanism in this system might be similar or different from other PD-1 inhibition studies? For instance, there is obviously no inflammatory cell recruitment occurring within the microspheres but perhaps TNF production leads to changes in population frequencies that impact bacterial control.

We demonstrate a change in macrophage polarisation as above (Figure 5---figure supplement 3) but accept that our in vitro system cannot model the complexity of an in vivo system, where cellular recruitment will play a role. We discuss the benefits and limitations of the in vitro model in the sixth paragraph of the Discussion.

> The study would be strengthened by an analysis to determine which cell type or mechanism is responsible for the excess TNF production following PD-1 blockade (CD4^+^ T cells, CD8^+^ T cells, or an innate cell type). At minimum, the authors should include a nuanced which of the mechanisms would be relevant to their model and why.

We completely agree that further detailed mechanistic study would strengthen the work, and we propose to address this by combining the microsphere system with single cell RNAseq, so that we can undertake detailed profiling of individual cellular phenotype within each condition. We can then determine phenotypic changes with PD-1 inhibition and how excess TNF leads to increased cell growth. However, this is an extensive programme of work, involving technical challenges of setting up single cell RNAseq in the containment level 3 laboratory, and cannot be performed within the time frame available. Therefore, to address the point, we have edited the manuscript as suggested to give a more nuanced discussion of the potential mechanism, and how they might be investigated, --in the sixth paragraph of the Discussion, as requested by the reviewers.
